NONINFECTIOUS VITRITIS AFTER INTRAVITREAL INJECTION OF ANTI-VEGF AGENTS: Variations in Rates and Presentation by Medication
The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
In Brief Purpose: The purpose of this study was to describe and compare the rates and characteristics of noninfectious vitritis after intravitreal injection of bevacizumab (Avastin, Genentech, South San Francisco, CA), ranibizumab (Lucentis, Genentech), and aflibercept (Eylea, Regeneron, Tarrytown, NY). Methods: A retrospective case series evaluated intravitreal injections from 2006 to 2013. Cases of inflammatory response were separated into culture-positive endophthalmitis, noninfectious vitritis (not treated with intravitreal antibiotics), and indeterminate. Noninfectious cases were analyzed for rate, presentation, and clinical course. Results: A total of 66,356 bevacizumab, 26,161 ranibizumab, and 8071 aflibercept injections were screened. The rates of noninfectious vitritis were 0.10% (67 cases) for bevacizumab, 0.02% (6 cases) for ranibizumab, and 0.16% (13 cases) for aflibercept. The differences were statistically significant based on Chi-square analysis (P < 0.001). Mean differences in visual decline were not significant by Kruskal–Wallis analysis (P = 0.12), but the percentage of patients with any visual decline did vary by medication according to Fisher exact test (P < 0.05). The percentage of patients with complaints of pain, blurred vision, and subjective floaters was not significantly different by medication based on Fisher exact testing (P = 0.2, P = 0.18, P = 0.16, respectively). Bevacizumab and aflibercept cases tended to present in separate chronological clusters. Conclusion: The results suggest a difference in rates of noninfectious vitritis for antivascular endothelial growth factor medications. Many cases tended to cluster instead of occurring at a consistent rate each year. Noninfectious inflammatory responses are uncommon occurrences after intravitreal injection of antivascular endothelial growth factor. This study describes differences in rates and clinical characteristics of vitritis after bevacizumab, ranibizumab, and aflibercept injections. Records of intravitreal injections from 2006 to 2013 were reviewed.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Less commonly, corneal edema, conjunctival injection, ocular pain, photophobia, hypopyon, keratic precipitates, trabeculitis, retinal infiltrates and hemorrhages may occur [2, 11, 12, 14, 16–19].”
From Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review (2021) · cites this paper as [12]
In the citing paper
“The overall incidence of sterile intraocular inflammation mimicking uveitis/endophthalmitis post injection has varied widely in the literature, with ranges from 0.005%–4.4% [11–13].”
From Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review (2021) · cites this paper as [12]
In the citing paper
“A large retrospective review reported rates of sterile endophthalmitis with aflibercept to be 0.16%, compared to 0.10% for bevacizumab and 0.02% with ranibizumab [12].”
From Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review (2021) · cites this paper as [12]
In the citing paper
“It has been shown that higher rates of inflammation occur with aflibercept and bevacizumab compared to ranibizumab [12].”
From Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review (2021) · cites this paper as [12]
Citations
Cites
Ranibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054481 · Cited by 5,886
Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration
Heier, J. S., Brown, D. M., Chong, V., Korobelnik, J.-F., Kaiser, P. K., Nguyen, Q. D., Kirchhof, B., Ho, A., Ogura, Y., Yancopoulos, G. D., et al. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.09.006 · Cited by 2,485 · cited 1×
“In the VIEW trials, adverse events were listed as vitreous floaters or endophthalmitis but not specifically as noninfectious vitritis.(11) The rate presented in this study for bevacizumab (0.”
BackgroundFung, A. E., Rosenfeld, P. J., & Reichel, E. (2006) · British Journal of Ophthalmology · doi:10.1136/bjo.2006.099598 · Cited by 532
Wu, L., Martínez-Castellanos, M. A., Quiroz-Mercado, H., Arevalo, J. F., Berrocal, M. H., Farah, M. E., Maia, M., Roca, J. A., Rodriguez, F. J., & for the Pan American Collaborative Retina Group (PACORES) (2007) · Graefe's Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-007-0660-z · Cited by 456 · cited 1×
“09% listed by the Pan-American Collaborative Study Group for bevacizumab.(12) The 0.”
BackgroundPilli, S., Kotsolis, A., Spaide, R. F., Slakter, J., Freund, K. B., Sorenson, J., Klancnik, J., & Cooney, M. (2008) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2007.12.036 · Cited by 181
Barza, M. J. (1997) · Archives of Ophthalmology · doi:10.1001/archopht.1997.01100160312008 · Cited by 149 · cited 1×
“The time delay for treatment is minimal, but aqueous aspirations yield lower growth rate on culture.(16) In this study, only cases that had no history of intravitreal antibiotics were defined as noninfectious.”
BackgroundWickremasinghe, S. S., Michalova, K., Gilhotra, J., Guymer, R. H., Harper, C. A., Wong, T. Y., & Qureshi, S. (2008) · Ophthalmology · doi:10.1016/j.ophtha.2008.05.007 · Cited by 124 · cited 1×
“Although pathophysiologic analyses of noninfectious cases are sparse, descriptions of noninfectious reactions have assisted clinicians in guiding therapy and counseling.(4,5) This study examines the rates of inflammatory reactions in an office-based multicenter private practice using commercial anti-VEGF product and c…”
BackgroundGoldberg, R. A., Shah, C. P., Wiegand, T. W., & Heier, J. S. (2014) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2014.06.019 · Cited by 94 · cited 1×
“37% presented recently in a cluster of aflibercept cases.(13) In this series, there was a significant difference in rate of noninfectious inflammation between the 3 antiVEGF agents used.”
BackgroundTabandeh, H., Boscia, F., Sborgia, A., Ciracì, L., Dayani, P. N., Mariotti, C., Furino, C., & Flynn, H. W. (2013) · Retina · doi:10.1097/iae.0000000000000008 · Cited by 84
Vitreous Inflammation Associated with Intravitreal Anti-VEGF Pharmacotherapy
Agrawal, S., Joshi, M., & Christoforidis, J. B. (2013) · Mediators of Inflammation · doi:10.1155/2013/943409 · Cited by 83 · cited 3×
“or preparation of the agent.(4) The etiologies could be multifactorial based on differences in the molecules, handling, and preparation of each medication.”
Background
Cited by
Anderson, W. J., da Cruz, N. F. S., Lima, L. H., Emerson, G. G., Rodrigues, E. B., & Melo, G. B. (2021) · International Journal of Retina and Vitreous · doi:10.1186/s40942-021-00307-7 · Cited by 155
Inflammatory Complications of Intravitreal Anti-VEGF Injections
Cox, J. T., Eliott, D., & Sobrin, L. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10050981 · Cited by 137
“Retrospective and prospective data suggest that the rates of SII from bevacizumab are significantly higher than those of ranibizumab or aflibercept [27,41,48].”
BackgroundResultInfluentialMelo, G. B., Cruz, N. F. S. D., Emerson, G. G., Rezende, F. A., Meyer, C. H., Uchiyama, S., Carpenter, J., Shiroma, H. F., Farah, M. E., Maia, M., et al. (2021) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2020.100862 · Cited by 114
Daïen, V., Nguyen, V., Essex, R. W., Morlet, N., Barthelmes, D., Gillies, M. C., Gillies, M. C., Hunt, A., Essex, R. W., Dayajeewa, C., et al. (2017) · Ophthalmology · doi:10.1016/j.ophtha.2017.07.005 · Cited by 110
Aflibercept-Related Sterile Intraocular Inflammation Outcomes
Greenberg, J. P., Belin, P., Butler, J., Feiler, D., Mueller, C., Tye, A., Friedlander, S. M., Emerson, G. G., & Ferrone, P. J. (2019) · Ophthalmology Retina · doi:10.1016/j.oret.2019.04.006 · Cited by 69
Metadata
- Authors
- Williams, P. D., Chong, D., Fuller, T., & Callanan, D.
- Affiliations
- Texas Retina Associates (United States) (US)
- Venue
- Retina
- Published
- 2016-05
- Volume
- 36
- Issue
- 5
- Pages
- 909-913
- ISSN
- 0275-004X (ISSN-L)
- OpenAlex
- W2331904769
- Cited by
- 69
- References
- 16
- Citations by year
- 2026: 5 · 2025: 12 · 2024: 5 · 2023: 4 · 2022: 8 · 2021: 13 · 2020: 6 · 2019: 8 · 2018: 4 · 2017: 4
- FWCI
- 2.56
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Retina (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Health Sciences › Medicine › Ophthalmology › Ocular Infections and Treatments
- Keywords
- intravitreal injection, VEGF inhibitors, bevacizumab, ranibizumab, aflibercept, endophthalmitis, visual deterioration, adverse events
- MeSH terms
- Bevacizumab, Ranibizumab, Aged, Aged, 80 and over, Eye Diseases, Female, Humans, Macular Degeneration, Male, Recombinant Fusion Proteins, Retinal Vein Occlusion, Retrospective Studies, Vitreous Body, Angiogenesis Inhibitors, Receptors, Vascular Endothelial Growth Factor, Vascular Endothelial Growth Factor A, Intravitreal Injections
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: NONINFECTIOUS VITRITIS AFTER INTRAVITREAL INJECTION OF ANTI-VEGF AGENTS: Variations in Rates and Presentation by Medication. https://app.cochat.ai/papers/10.1097/iae.0000000000000801
- The paper
- Williams, P. D., Chong, D., Fuller, T., & Callanan, D. (2016). NONINFECTIOUS VITRITIS AFTER INTRAVITREAL INJECTION OF ANTI-VEGF AGENTS: Variations in Rates and Presentation by Medication. Retina. https://doi.org/10.1097/iae.0000000000000801
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.